Cell Source Stock Performance
| CLCS Stock | USD 0.54 0.04 8.00% |
Cell Source holds a performance score of 7 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.0457, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cell Source's returns are expected to increase less than the market. However, during the bear market, the loss of holding Cell Source is expected to be smaller as well. Use Cell Source sortino ratio and the relationship between the downside variance and market facilitation index , to analyze future returns on Cell Source.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Cell Source are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental indicators, Cell Source unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 245.1 K | |
| Free Cash Flow | -3.4 M |
Cell |
Cell Source Relative Risk vs. Return Landscape
If you would invest 44.00 in Cell Source on August 31, 2024 and sell it today you would earn a total of 10.00 from holding Cell Source or generate 22.73% return on investment over 90 days. Cell Source is currently generating 1.5535% in daily expected returns and assumes 16.6554% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Cell, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cell Source Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cell Source's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Cell Source, and traders can use it to determine the average amount a Cell Source's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0933
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CLCS | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 16.66 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.55 actual daily | 30 70% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Cell Source is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cell Source by adding it to a well-diversified portfolio.
Cell Source Fundamentals Growth
Cell OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Cell Source, and Cell Source fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cell OTC Stock performance.
| Return On Asset | -3.78 | |||
| Current Valuation | 59.65 M | |||
| Shares Outstanding | 35.25 M | |||
| Price To Earning | (3.28) X | |||
| EBITDA | (4.11 M) | |||
| Cash And Equivalents | 93.09 K | |||
| Total Debt | 6.5 M | |||
| Debt To Equity | (1.04) % | |||
| Book Value Per Share | (0.34) X | |||
| Cash Flow From Operations | (3.38 M) | |||
| Earnings Per Share | (0.20) X | |||
| Total Asset | 313.77 K | |||
| Retained Earnings | (21.7 M) | |||
| Current Asset | 213.56 K | |||
| Current Liabilities | 8 M | |||
About Cell Source Performance
Assessing Cell Source's fundamental ratios provides investors with valuable insights into Cell Source's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cell Source is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.Things to note about Cell Source performance evaluation
Checking the ongoing alerts about Cell Source for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Cell Source help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cell Source is way too risky over 90 days horizon | |
| Cell Source has some characteristics of a very speculative penny stock | |
| Cell Source appears to be risky and price may revert if volatility continues | |
| Cell Source currently holds 6.5 M in liabilities. Cell Source has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cell Source until it has trouble settling it off, either with new capital or with free cash flow. So, Cell Source's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cell Source sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cell to invest in growth at high rates of return. When we think about Cell Source's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cell Source currently holds about 93.09 K in cash with (3.38 M) of positive cash flow from operations. | |
| Roughly 32.0% of the company shares are held by company insiders |
- Analyzing Cell Source's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cell Source's stock is overvalued or undervalued compared to its peers.
- Examining Cell Source's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cell Source's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cell Source's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Cell Source's otc stock. These opinions can provide insight into Cell Source's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cell OTC Stock Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.